Metalytics develops and delivers predictive Digital Twins to advance biopharmaceutical and biomanufacturing process development and manufacturing. Metalytics' MFATwin digital twins of cell culture processes lead to superior productivity, product quality and process robustness. Groundbreaking predictive power is achieved by exploiting process data using artificial intelligence and biochemical networks. Metalytics' unique approach substantially reduces experimental effort, costs of goods and time to market. Leading biopharmaceutical companies worldwide use our technology for cell line development and media design.

Metalytics provides critical information about cellular metabolic rates in living cells, in vitro and in vivo, giving actionable results which can be implemented to accelerate research, development, and manufacturing timelines. Our CoreMFA Big Data platform allows investigators to quickly and rationally engineer improved cells and/or optimize cell culture media components with applications in a diversity of industries, including biopharma and specialty chemical manufacturing, biofuels and bioproducts production, synthetic biology, agricultural biotechnology, and cell-based protein and food production. By highlighting the most promising engineering targets in metabolism, reduced time-to-market, increased production quantity and quality, lower capital requirements, and reduced raw material costs can be achieved.

​

​